157 related articles for article (PubMed ID: 36940637)
1. FOXM1 augments sorafenib resistance and promotes progression of hepatocellular carcinoma by epigenetically activating KIF23 expression.
Zhu C; Guo H; Ma Z; Shi S; Zhao X; Zhai D; Zhou X; Jiang P; Xu Q; Cai J
Biochem Biophys Res Commun; 2023 May; 656():1-9. PubMed ID: 36940637
[TBL] [Abstract][Full Text] [Related]
2. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
[TBL] [Abstract][Full Text] [Related]
3. Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells.
Yan D; Yan X; Dai X; Chen L; Sun L; Li T; He F; Lian J; Cai W
Oncol Rep; 2019 Aug; 42(2):785-796. PubMed ID: 31233189
[TBL] [Abstract][Full Text] [Related]
4. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
[TBL] [Abstract][Full Text] [Related]
6. MiR-3677-3p promotes development and sorafenib resistance of hepatitis B-related hepatocellular carcinoma by inhibiting FOXM1 ubiquitination.
He H; Zhou J; Cheng F; Li H; Quan Y
Hum Cell; 2023 Sep; 36(5):1773-1789. PubMed ID: 37402927
[TBL] [Abstract][Full Text] [Related]
7. The critical role of dysregulated Hh-FOXM1-TPX2 signaling in human hepatocellular carcinoma cell proliferation.
Wang Y; Wang H; Yan Z; Li G; Hu G; Zhang H; Huang D; Wang Y; Zhang X; Yan Y; Lu Q; Cheng M; Luo S
Cell Commun Signal; 2020 Jul; 18(1):116. PubMed ID: 32723329
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1.
Chai N; Xie HH; Yin JP; Sa KD; Guo Y; Wang M; Liu J; Zhang XF; Zhang X; Yin H; Nie YZ; Wu KC; Yang AG; Zhang R
Biochem Biophys Res Commun; 2018 Jun; 500(4):924-929. PubMed ID: 29705704
[TBL] [Abstract][Full Text] [Related]
9. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma.
Zhang B; Zhang Y; Zou X; Chan AW; Zhang R; Lee TK; Liu H; Lau EY; Ho NP; Lai PB; Cheung YS; To KF; Wong HK; Choy KW; Keng VW; Chow LM; Chan KK; Cheng AS; Ko BC
J Pathol; 2017 Dec; 243(4):418-430. PubMed ID: 28862757
[TBL] [Abstract][Full Text] [Related]
10. DEP domain containing 1B (DEPDC1B) exerts the tumor promoter in hepatocellular carcinoma through activating p53 signaling pathway via kinesin family member 23 (KIF23).
Shen E; Zhang J; Lu Y
Bioengineered; 2022 Jan; 13(1):1103-1114. PubMed ID: 34983303
[TBL] [Abstract][Full Text] [Related]
11. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
13. Downreguation of FoxM1 by miR-214 inhibits proliferation and migration in hepatocellular carcinoma.
Tian C; Wu H; Li C; Tian X; Sun Y; Liu E; Liao X; Song W
Gene Ther; 2018 Jul; 25(4):312-319. PubMed ID: 29973656
[TBL] [Abstract][Full Text] [Related]
14. Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway.
Park YH; Kim SU; Kwon TH; Kim JM; Song IS; Shin HJ; Lee BK; Bang DH; Lee SJ; Lee DS; Chang KT; Kim BY; Yu DY
Oncogene; 2016 Jul; 35(27):3503-13. PubMed ID: 26500057
[TBL] [Abstract][Full Text] [Related]
15. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
16. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
17. [MicroRNA 424-5p promotes the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting Kinesin family member 23].
Liu XL; Sun CF; Yuan Y; Sheng YJ; Deng CL
Zhonghua Gan Zang Bing Za Zhi; 2022 Oct; 30(10):1074-1081. PubMed ID: 36727232
[No Abstract] [Full Text] [Related]
18. FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer Cells.
Wuputra K; Hsiao PJ; Chang WT; Wu PH; Chen LA; Huang JW; Su WL; Yang YH; Wu DC; Yokoyama KK; Kuo KK
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887129
[TBL] [Abstract][Full Text] [Related]
19. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
20. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
Sun J; Zheng X; Wang B; Cai Y; Zheng L; Hu L; Lu X; Xie S; Zhang X; Liu H; Ye L
Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):261-270. PubMed ID: 35130616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
